门冬胰岛素30与人胰岛素30R治疗2型糖尿病临床比较  

Comparison of the Effect and Safety between Premixed Insulin Aspart 30 and Human Insulin Premix 70/30 in the Patients with type 2 Diabetes

作　　者：韩冬[1] 赵秋菊[1] 周萍[1] 

机构地区：[1]江苏省连云港市第二人民医院内分泌科,222023

出　　处：《医学理论与实践》2007年第12期1386-1387,共2页The Journal of Medical Theory and Practice

摘　　要：目的:比较门冬胰岛素30与人胰岛素30R治疗2型糖尿病的疗效及低血糖风险。方法:81例2型糖尿病患者随机分为门冬胰岛素30组与人胰岛素30R组,在口服瑞格列奈1.5mg/d基础上,采用每日早晚皮下注射门冬胰岛素30与人胰岛素30R,进行为期4周的观察。比较4周后两组8个时点血糖,糖化血红蛋白(HbA1c)、低血糖事件的差异。结果:门冬胰岛素30组与人胰岛素30R组治疗后血糖较治疗前均明显下降,门冬胰岛素30组早晚餐后2h血糖低于人胰岛素30R组,差异有统计学意义(P<0.05),门冬胰岛素30组低血糖发生次数低于人胰岛素30R组,但差异无统计学意义(P>0.05),糖化血红蛋白水平无统计学差异。结论:对于2型糖尿病患者,每日两次注射门冬胰岛素30较人胰岛素30R对餐后2h血糖控制更有效,减少低血糖风险,为患者提供更灵活的用餐时间。Objective： To compare the effect and safety between premixed insulin aspart 30 and human insulin premix 70/30 in the patients with type 2 diabetes. Methods 81 patients with type 2 diabetes were randomly divided into groups of receiving premixed insulin aspart 30 and human insulin premix 70/30 for 4 weeks. Blood glucose and HbA1c were measured and compared before and after the insulin treatments Results： After the treatments, 2 hours postprandial glucose levels after breakfast and dinner were significantly decreased （P〈0. 05）. However, HbA1c and the risk of hypoglycaemia did not differ significantly between the treatments. Conclusion： Treatment of diabetic patients with premixed insulin aspart 30 can more significantly improve 2 hours postprandial blood glucose level compared to treatment with human insulin premix 70/30 ,without increasing the risk of hypoglycaemia.

关 键 词：门冬胰岛素30 人胰岛素30R 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]